tetano
Editor, Senior Moderator
Diagn Microbiol Infect Dis
. 2020 Dec 24;99(4):115294.
doi: 10.1016/j.diagmicrobio.2020.115294. Online ahead of print.
Evaluation of a commercially-available surrogate virus neutralization test for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
Emelissa J Valcourt[SUP] 1 [/SUP], Kathy Manguiat[SUP] 2 [/SUP], Alyssia Robinson[SUP] 2 [/SUP], Julie Chih-Yu Chen[SUP] 3 [/SUP], Kristina Dimitrova[SUP] 2 [/SUP], Clark Philipson[SUP] 2 [/SUP], Lise Lamoureux[SUP] 2 [/SUP], Elizabeth McLachlan[SUP] 4 [/SUP], Zachary Schiffman[SUP] 5 [/SUP], Michael A Drebot[SUP] 5 [/SUP], Heidi Wood[SUP] 6 [/SUP]
Affiliations
Abstract
There remains an urgent need for assays to quantify humoral protective immunity to SARS-CoV-2 to understand the immune responses of COVID-19 patients, evaluate efficacy of vaccine candidates in clinical trials, and conduct large-scale epidemiological studies. The plaque-reduction neutralization test (PRNT) is the reference-standard for quantifying antibodies capable of neutralizing SARS-CoV-2. However, the PRNT is logistically demanding, time-consuming, and requires containment level-3 facilities to safely work with live virus. In contrast, a surrogate virus neutralization test (sVNT) manufactured by Genscript is a quick and simple assay that detects antibodies that inhibit the RBD-ACE2 interaction, crucial for virus entry into host cells. In this study, we evaluate the sensitivity, specificity, and cross-reactivity of the sVNT compared with the PRNT using both 50% and 90% SARS-CoV-2 neutralization as a reference-standard. We found that the sVNT provides a high-throughput screening tool prior to confirmatory PRNT testing for the evaluation of SARS-CoV-2 neutralizing antibodies.
Keywords: COVID-19; Immunity; Neutralization test.
. 2020 Dec 24;99(4):115294.
doi: 10.1016/j.diagmicrobio.2020.115294. Online ahead of print.
Evaluation of a commercially-available surrogate virus neutralization test for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
Emelissa J Valcourt[SUP] 1 [/SUP], Kathy Manguiat[SUP] 2 [/SUP], Alyssia Robinson[SUP] 2 [/SUP], Julie Chih-Yu Chen[SUP] 3 [/SUP], Kristina Dimitrova[SUP] 2 [/SUP], Clark Philipson[SUP] 2 [/SUP], Lise Lamoureux[SUP] 2 [/SUP], Elizabeth McLachlan[SUP] 4 [/SUP], Zachary Schiffman[SUP] 5 [/SUP], Michael A Drebot[SUP] 5 [/SUP], Heidi Wood[SUP] 6 [/SUP]
Affiliations
- PMID: 33387896
- DOI: 10.1016/j.diagmicrobio.2020.115294
Abstract
There remains an urgent need for assays to quantify humoral protective immunity to SARS-CoV-2 to understand the immune responses of COVID-19 patients, evaluate efficacy of vaccine candidates in clinical trials, and conduct large-scale epidemiological studies. The plaque-reduction neutralization test (PRNT) is the reference-standard for quantifying antibodies capable of neutralizing SARS-CoV-2. However, the PRNT is logistically demanding, time-consuming, and requires containment level-3 facilities to safely work with live virus. In contrast, a surrogate virus neutralization test (sVNT) manufactured by Genscript is a quick and simple assay that detects antibodies that inhibit the RBD-ACE2 interaction, crucial for virus entry into host cells. In this study, we evaluate the sensitivity, specificity, and cross-reactivity of the sVNT compared with the PRNT using both 50% and 90% SARS-CoV-2 neutralization as a reference-standard. We found that the sVNT provides a high-throughput screening tool prior to confirmatory PRNT testing for the evaluation of SARS-CoV-2 neutralizing antibodies.
Keywords: COVID-19; Immunity; Neutralization test.